These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37129299)

  • 1. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis.
    Morgan A; Tallantyre E; Ontaneda D
    Expert Rev Neurother; 2023 May; 23(5):433-444. PubMed ID: 37129299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis: What Is the Future of Multiple Sclerosis Treatment?
    Bou Rjeily N; Mowry EM; Ontaneda D; Carlson AK
    Neurol Clin; 2024 Feb; 42(1):185-201. PubMed ID: 37980115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.
    Ontaneda D; Tallantyre EC; Raza PC; Planchon SM; Nakamura K; Miller D; Hersh C; Craner M; Bale C; Chaudhry B; Gunzler DD; Love TE; Gerry S; Coles A; Cohen JA; Evangelou N
    Contemp Clin Trials; 2020 Aug; 95():106009. PubMed ID: 32320842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
    JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.
    Smets I; Versteegh M; Huygens S; Wokke B; Smolders J
    Mult Scler; 2024 Jul; 30(8):1016-1025. PubMed ID: 38859625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
    Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
    Havrdova E; Hutchinson M; Kurukulasuriya NC; Raghupathi K; Sweetser MT; Dawson KT; Gold R
    Expert Opin Pharmacother; 2013 Oct; 14(15):2145-56. PubMed ID: 23971970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.
    Ontaneda D; Tallantyre E; Kalincik T; Planchon SM; Evangelou N
    Lancet Neurol; 2019 Oct; 18(10):973-980. PubMed ID: 31375366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
    Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R
    Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
    Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
    JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.